Long-acting slow effective release antiretroviral therapy

Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs

(2017) Divya Prakash Gnanadhas et al.   JOURNAL OF CLINICAL INVESTIGATION

Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS

(2016) Madhavan Nair et al.   ADVANCED DRUG DELIVERY REVIEWS

Tracking development assistance for HIV/AIDS

(2016) Matthew T. Schneider et al.   AIDS

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

(2016) Adrian S. Ray et al.   ANTIVIRAL RESEARCH

Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia

(2016) Yvette N. Lamb et al.   DRUGS

Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1

(2016) Maarten Danial et al.   MOLECULAR PHARMACEUTICS

Development and characterization of a long-acting nanoformulated abacavir prodrug

(2016) Dhirender Singh et al.   Nanomedicine

Persistent HIV-1 replication maintains the tissue reservoir during therapy

(2016) Ramon Lorenzo-Redondo et al.   NATURE

International AIDS Society global scientific strategy: towards an HIV cure 2016

(2016) Steven G Deeks et al.   NATURE MEDICINE

Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable

(2016) Michael A. Collier et al.   PHARMACEUTICAL RESEARCH

The promise and pitfalls of long-acting injectable agents for HIV prevention

(2016) Raphael J. Landovitz et al.   Current Opinion in HIV and AIDS

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV

(2016) Alison L. Hill et al.   PLoS Pathogens

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

(2016) Ian McGowan et al.   Lancet HIV

Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing

(2016) Rafal Kaminski et al.   Scientific Reports

Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates

(2015) Jennifer P. Freeling et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice

(2015) Pavan Puligujja et al.   ANTIVIRAL RESEARCH

Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations

(2015) Pavan Puligujja et al.   BIOMATERIALS

Embracing failure: What the Phase III progesterone studies can teach about TBI clinical trials

(2015) Donald G. Stein   BRAIN INJURY

Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs – Modern Trojan horses to combat HIV

(2015) Lakshmi Narashimhan Ramana et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Sustained-release nanoART formulation for the treatment of neuroAIDS

(2015) Rahul Jayant et al.   International Journal of Nanomedicine

Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice

(2015) Luisa Fiandra et al.   Nanomedicine-Nanotechnology Biology and Medicine

Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages

(2015) Mariluz Araínga et al.   Retrovirology

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

(2015) Chasity D. Andrews et al.   Science Translational Medicine

Long-acting rilpivirine for HIV prevention

(2015) Akil Jackson et al.   Current Opinion in HIV and AIDS

Cabotegravir long-acting for HIV-1 prevention

(2015) Chasity D. Andrews et al.   Current Opinion in HIV and AIDS

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission

(2015) Martina Kovarova et al.   PLoS Pathogens

Prodrug and conjugate drug delivery strategies for improving HIV/AIDS therapy

(2015) M.S. Palombo et al.   JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings

(2014) Marco Vitoria et al.   ANTIVIRAL THERAPY

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

(2014) A G A Jackson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies

(2014) Benson Edagwa et al.   CURRENT MEDICINAL CHEMISTRY

Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes

(2014) Benson J. Edagwa et al.   FASEB JOURNAL

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Mental, Neurological, and Substance Use Disorders in People Living With HIV/AIDS in Low- and Middle-Income Countries

(2014) Dixon Chibanda et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy

(2013) Nagsen Gautam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia

(2013) Eun Ji Park et al.   ARCHIVES OF PHARMACAL RESEARCH

Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology

(2013) Kim E. Sapsford et al.   CHEMICAL REVIEWS

Common AIDS-associated opportunistic infections

(2013) E. Ong   CLINICAL MEDICINE

Emerging strategies to deplete the HIV reservoir

(2013) Nancie M. Archin et al.   CURRENT OPINION IN INFECTIOUS DISEASES

The New Small-Molecule Mixed-Lineage Kinase 3 Inhibitor URMC-099 Is Neuroprotective and Anti-Inflammatory in Models of Human Immunodeficiency Virus-Associated Neurocognitive Disorders

(2013) D. F. Marker et al.   JOURNAL OF NEUROSCIENCE

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients

(2013) Qing Ma et al.   JOURNAL OF NEUROVIROLOGY

Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections

(2013) Pavan Puligujja et al.   Nanomedicine-Nanotechnology Biology and Medicine

Long-acting injectable antiretrovirals for HIV treatment and prevention

(2013) William R. Spreen et al.   Current Opinion in HIV and AIDS

Overcoming pharmacologic sanctuaries

(2013) Theodore J. Cory et al.   Current Opinion in HIV and AIDS

Long-Acting Antipsychotic Medications

(2012) Raman Baweja et al.   CURRENT DRUG TARGETS

Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

(2012) Michael C. Thigpen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

(2012) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tuberculosis and HIV Co-Infection

(2012) Andrzej Pawlowski et al.   PLoS Pathogens

Human Immunodeficiency Virus type 1 Endocytic Trafficking Through Macrophage Bridging Conduits Facilitates Spread of Infection

(2011) Irena Kadiu et al.   Journal of Neuroimmune Pharmacology

Activity and Safety of Synthetic Lectins Based on Benzoboroxole-Functionalized Polymers for Inhibition of HIV Entry

(2011) Alamelu Mahalingam et al.   MOLECULAR PHARMACEUTICS

Macrophage endocytic trafficking of antiretroviral nanoparticles

(2011) Irena Kadiu et al.   Nanomedicine

Prodrugs--from Serendipity to Rational Design

(2011) K. M. Huttunen et al.   PHARMACOLOGICAL REVIEWS

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

(2010) G. van 't Klooster et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment‐Naive, HIV‐1–Infected Individuals Commencing cART? A Randomized, Controlled Study

(2010) Alan Winston et al.   CLINICAL INFECTIOUS DISEASES

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

(2010) Q. Abdool Karim et al.   SCIENCE

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

(2009) Christina M Marra et al.   AIDS

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

(2009) Lieven Baert et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS

(2009) H. Dou et al.   JOURNAL OF IMMUNOLOGY

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte–macrophage drug delivery

(2009) Ari S Nowacek et al.   Nanomedicine

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

The Challenge of Finding a Cure for HIV Infection

(2009) D. D. Richman et al.   SCIENCE

Prodrugs: design and clinical applications

(2008) Jarkko Rautio et al.   NATURE REVIEWS DRUG DISCOVERY